ArticleCurrent therapeutic research, clinical and experimental2024
Immunogenicity and Potential for Intraocular Inflammation of Intravitreal Anti-VEGF Drugs.
Article in Current therapeutic research, clinical and experimental, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 12 citations in OpenAlex.
- Insights into the modulation of age-related macular degeneration: Molecular and systems-level perspectives.Acta ophthalmologica · 2026Article
- Endophthalmitis rates following intravitreal injection of aflibercept using a prefilled syringe - a multicenter study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Use of brolucizumab in refractory neovascular age-related macular degeneration: characteristics and biomarkers of intraocular inflammation from an Asian real-world study.Japanese journal of ophthalmology · 2026Article
- Anti-vascular endothelial growth factor therapy in uveitis: Bridging inflammation and vascular pathology.Indian journal of ophthalmology · 2026Review
- Design and characterization of intravitreal bevacizumab-loaded PLGA nanoparticles: pharmacokinetic and biodistribution impact.Drug delivery and translational research · 2026Article
- In-Depth Analysis of the Intravitreal Biocompatibility of Polyethylene Glycol of Different Molecular Weight in an In Vivo Porcine Model.Investigative ophthalmology & visual science · 2026Article
- Two-in-one protein tag enables the soluble expression and calcium-dependent purification of single-chain antibody fragments.Communications biology · 2026Article
- Intraocular inflammation after intravitreal injection of faricimab-a case series including one case of bilateral choroidal involvement.International journal of ophthalmology · 2026Article
- Systemic and ocular complications related to intravitreal administration of anti-VEGF agents.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
- Bilateral Sterile Intraocular Inflammation Following Intravitreal Aflibercept 8 mg Injections: A Case Report.Reports (MDPI) · 2025Article
- Consensus of Expert Recommendations for the Safe Administration of Brolucizumab in Neovascular Age-related Macular Degeneration.Korean journal of ophthalmology : KJO · 2025Article
- Recent advances in engineered exosome-based therapies for ocular vascular disease.Journal of nanobiotechnology · 2025Review
- Aflibercept 2 mg biosimilars-will they lead the Anti-VEGF biosimilar world globally.Eye (London, England) · 2025Article
- Changes in Aqueous Humor Cytokine Profile Following Intravitreal Brolucizumab Injection.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Dynamics of Treatment Response to Faricimab for Diabetic Macular Edema.Bioengineering (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Concerns of intraocular inflammation associated with intravitreal administration of anti-VEGF drugs have been risen and the exact mechanism is not yet elucidated. Objective: To explore the relationship between immunogenicity and intraocular inflammation in intravitreal anti-VEGF drugs. Methods: This review examines the immunogenicity of individual intravitreal anti-VEGF drugs and their potential link to intraocular inflammation. Results: We suggest that the main cause of intraocular inflammation is the presence of pre-existing and treatment-induced antidrug antibodies, along with considerations related to the molecular structure, which includes the drug's format and size. Conclusions: Researchers and clinicians involved in the advancement of new anti-VEGF drugs should take into consideration the factors related to intraocular inflammation that have been discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.